Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 25:13:985670.
doi: 10.3389/fphar.2022.985670. eCollection 2022.

Insights on prospects of nano-siRNA based approaches in treatment of Cancer

Rajat Goyal  1   2 , Hitesh Chopra  3 , Inderbir Singh  3 , Kamal Dua  4 , Rupesh K Gautam  1
Affiliations
Review

Insights on prospects of nano-siRNA based approaches in treatment of Cancer

Rajat Goyal et al. Front Pharmacol. .

Abstract

siRNA interference, commonly referred to as gene silence, is a biological mechanism that inhibits gene expression in disorders such as cancer. It may enhance the precision, efficacy, and stability of medicines, especially genetic therapies to some extent. However, obstacles such as the delivery of oligonucleotide drugs to inaccessible areas of the body and the prevalence of severe side effects must be overcome. To maximize their potential, it is thus essential to optimize their distribution to target locations and limit their toxicity to healthy cells. The action of siRNA may be harnessed to delete a similar segment of mRNA that encodes a protein that causes sickness. The absence of an efficient delivery mechanism that shields siRNA from nuclease degradation, delivers it to cancer cells and releases it into the cytoplasm of specific cancer cells without causing side effects is currently the greatest obstacle to the practical implementation of siRNA therapy. This article focuses on combinations of siRNA with chemotherapeutic drug delivery systems for the treatment of cancer and gives an overview of several nanocarrier formulations in both research and clinical applications.

Keywords: cancer; exosomes; gene silencing; nanomaterials; nanoparticles; siRNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
The mechanism of gene silencing by siRNAs.
FIGURE 2
FIGURE 2
Postoperative breast cancer metastatic suppression via exosome-mediated siRNA delivery.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abnous K., Danesh N. M., Ramezani M., Charbgoo F., Bahreyni A., Taghdisi S. M. (2018). Targeted delivery of doxorubicin to cancer cells by a cruciform DNA nanostructure composed of AS1411 and FOXM1 aptamers. Expert Opin. Drug Deliv. 15, 1045–1052. 10.1080/17425247.2018.1530656 - DOI - PubMed
    1. Agrawal A. K., Aqil F., Jeyabalan J., Spencer W. A., Beck J., Gachuki B. W., et al. (2017). Milk-derived exosomes for oral delivery of paclitaxel. Nanomedicine 13, 1627–1636. 10.1016/j.nano.2017.03.001 - DOI - PubMed
    1. Ali H. M., Urbinati G., Raouane M., Massaad-Massade L. (2012). Significance and applications of nanoparticles in siRNA delivery for cancer therapy. Expert Rev. Clin. Pharmacol. 5, 403–412. 10.1586/ecp.12.33 - DOI - PubMed
    1. Allen T. M., Cullis P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Adv. Drug Deliv. Rev. 65, 36–48. 10.1016/j.addr.2012.09.037 - DOI - PubMed
    1. Alshaer W., Hillaireau H., Vergnaud J., Mura S., Deloménie C., Sauvage F., et al. (2018). Aptamer-guided siRNA-loaded nanomedicines for systemic gene silencing in CD-44 expressing murine triple-negative breast cancer model. J. Control. Release 271, 98–106. 10.1016/j.jconrel.2017.12.022 - DOI - PubMed

LinkOut - more resources